



Lonnie Shoff Joins Henry Schein as President, Henry Schein Global Healthcare Specialties Group

September 24, 2009

MELVILLE, N.Y., Sept. 24 /PRNewswire-FirstCall/ -- Henry Schein, Inc. (Nasdaq: HSIC), the largest distributor of healthcare products and services to office-based practitioners, today announced the appointment of Lonnie Shoff to the newly-created position of President, Henry Schein Global Healthcare Specialties Group. In her new position, Ms. Shoff will join the Company's Executive Management Committee and report to Henry Schein Chairman and Chief Executive Officer, Stanley M. Bergman.

(Photo: <http://www.newscom.com/cgi-bin/prnh/20090924/NY81301>)

"Lonnie's proven leadership skills will help drive our Company's future growth by increasing our focus on the pursuit of businesses that complement our North American and International Groups," said Mr. Bergman. "Lonnie's portfolio will include building our specialty businesses and expanding our exclusive and semi-exclusive product and service offerings. The newly-formed Henry Schein Global Healthcare Specialties Group that Lonnie will lead reflects the strong entrepreneurial spirit that has driven our Company since we were founded in 1932. It will be instrumental as we continue to transform our Company to become even more relevant to our customers around the world and help drive the success of our customers' practices."

Within the new Henry Schein Global Healthcare Specialties Group, Ms. Shoff will be responsible for Henry Schein Global Dental Specialties and Henry Schein Global Exclusive Brands. Sales from these businesses will continue to be reported as part of the Company's Dental, Medical and International Groups.

Ms. Shoff joins Henry Schein from Roche Diagnostics, where she held a series of increasingly responsible positions in the United States and Switzerland over the past 20 years, focusing on applied science, molecular diagnostics, global business development, and marketing and business management. Most recently, Ms. Shoff served as Senior Vice President & General Manager, Applied Science, leading the U.S. commercial operations for this \$350 million group.

Ms. Shoff has managed the life cycles of more than 2,500 products, and nurtured ventures from seed funding through product launch. While at Roche Diagnostics, Ms. Shoff also built a Global Internal Venturing Program, which the London School of Business praised in its book, *Inventing: Why Big Companies Must Think Small*. Ms. Shoff earned a bachelor's degree in Biological Sciences from Purdue University and attended graduate school for Genetics at Temple University.

About Henry Schein

Henry Schein, a Fortune 500(R) company and a member of the NASDAQ 100(R) Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 575,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items. Henry Schein also provides exclusive, innovative technology offerings for dental, medical and veterinary professionals, including value-added practice management software and electronic health record solutions.

Headquartered in Melville, N.Y., Henry Schein employs over 12,500 people and has operations or affiliates in 23 countries. The Company's net sales reached a record \$6.4 billion in 2008. For more information, visit the Henry Schein Web site at www.henryschein.com.

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: decreased customer demand and changes in vendor credit terms; disruptions in financial markets; general economic conditions; competitive factors; changes in the healthcare industry; changes in regulatory requirements that affect us; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service issues with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any

forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

SOURCE Henry Schein, Inc.

Investors, Steven Paladino, Executive Vice President and Chief Financial Officer, +1-631-843-5500, steven.paladino@henryschein.com, or Media, Susan Vassallo, Vice President, Corporate Communications, +1-631-843-5562, susan.vassallo@henryschein.com, both of Henry Schein, Inc